Search Results 571-580 of 18042 for Alopecia

1. ACP-196 in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies - Mayo Clinic

   Note: Subjects with Grade ≤ 2 neuropathy or Grade ≤ 2 alopecia are an exception to the latter criterion and may qualify for the study. Women who are ...

2. A Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency - Mayo Clinic

   Adverse effect of prior therapy not resolved to CTCAE Grade 1 or below with the exception of alopecia. Ongoing Grade 2 non-hematologic toxicity related to ...

3. Study of Imprime PGG and Pembrolizumab in Advanced Melanoma and Triple Negative Breast Cancer - Mayo Clinic

   ... alopecia. If subject received major surgery or radiation therapy of > 30 Gy, must have recovered from the toxicity and/or complications from the ...

4. A Phase 1/2a Dose-Finding Study of PT-112 in Patients With Relapsed or Refractory Multiple Myeloma - Mayo Clinic

   Recovery from non-hematologic toxic effects of prior therapy to grade ≤ 1 (except alopecia) by NCI CTCAE Version 4.03. Adequate bone marrow (BM), renal ...

5. A Study of Tyrosine Kinase Inhibitor ICP-022 in Patients With r/r B-Cell Malignancies - Mayo Clinic

   0) ≤ Grade 1, or to the levels dictated in the eligibility criteria with the exception of alopecia. Patient with history of confirmed progressive ...

6. A Study of Sonodynamic Therapy Using SONALA-001 and Exablate 4000 Type 2.0 in Subjects With Recurrent GBM - Mayo Clinic

   current) related to prior anticancer therapy (excluding alopecia, lymphopenia, peripheral neuropathy, and ototoxicity, which are excluded only if ≥ Grade 3) ...

7. Study of Azacitidine With or Without Birinapant in Subjects With MDS or CMMoL - Mayo Clinic

   ... alopecia) due to therapy administered prior to the initiation of study drug dosing. Nursing or pregnant. Known allergy or hypersensitivity to any of the ...

8. A Study Using Targeted Inhibitors to Treat Specific Tumor Mutations in Patients with Meningiomas - Mayo Clinic

   ... alopecia and fatigue; No craniotomy within 28 days of registration. Not pregnant and not nursing. A female of childbearing potential is a sexually mature ...

9. Carboplatin and Gemcitabine Hydrochloride With or Without VX-970 in Treating Patients With Recurrent and Metastatic Ovarian, Primary Peritoneal, or Fallopian Tube Cancer - Mayo Clinic

   ... alopecia. Patients with treatment related effects, such as peripheral neuropathy, that are grade 1 or less are eligible. Prior exposure to gemcitabine ...

10. Phase III Study Of Datopotamab Deruxtecan Versus Docetaxel In Previously Treated TROP2-positive Advanced Non-squamous NSCLC Without AGA - Mayo Clinic

    Participation eligibility · Persistent toxicities caused by previous anti-cancer therapy, excluding alopecia, not yet improved to Grade ≤ 1 or baseline. · Has ...